First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

British Journal of Cancer, Published online: 26 January 2021; doi:10.1038/s41416-020-01229-1First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Source: British Journal of Cancer - January 26, 2021 Category: Cancer & Oncology Authors: Jesper van Breeschoten Michel W. J. M. Wouters Doranne L. Hilarius John B. Haanen Christian U. Blank Maureen J. B. Aarts Franchette W. P. J. van den Berkmortel Jan-Willem B. de Groot Geke A. P. Hospers Ellen Kapiteijn Djura Piersma Roos S. van Rijn Karijn Source Type: research